

**Listing of Claims**

The claims in this listing will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1-7. (Canceled)

8. (Currently Amended) A method of increasing apoptotic effect of cytostatics after chemotherapy comprising administering a 5 substituted nucleoside comprising (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), salt, prodrug or mixture thereof, the administering being without administration of a cytostatic, during a recovery phase after a cytostatic chemotherapy cycle, wherein the cytostatic chemotherapy cycle includes administration of (a) BVDU, prodrug, or salt, or mixture thereof and (b) a cytostatic.

9. (Canceled)


10. (Currently Amended) The method of claim [[9]] 8 wherein during the cytostatic chemotherapy cycle, administered amounts of cytostatic are increased over a period of the cytostatic chemotherapy cycle, and the administered amount of BVDU, salt, prodrug, or combination thereof is constant.

11. (Previously Presented) The method of claim 10 wherein the recovery phase has a duration of from 3 to 10 days.

12. (Currently Amended) The method of claim 10 wherein the cytostatic chemotherapy cycle has a duration of from 8 to 30 days.

13-14. (Canceled)

15. (Currently Amended) The method of claim 28 ~~wherein the 5-substituted nucleoside administered comprising administering~~ during the cytostatic chemotherapy cycle comprises a compound the BVDU prodrug of the general formula I:



16. (Currently Amended) The method of claim 8 wherein the administration provides a 5-substituted nucleoside blood concentration between 0.02 and 50 µg/ml during the recovery phase.

17. (Currently Amended) The method of claim [[9]] 8 wherein the cytostatic comprises doxorubicin, mitoxantrone, mitomycin C, or methotrexate.

18. (Canceled)

19. (Previously Presented) The method of claim 28 wherein the administration provides a 5-substituted nucleoside blood concentration between 0.02 and 50 µg/ml during the recovery phase.

20. (Previously Presented) The method of claim 15 wherein the cytostatic comprises doxorubicin, mitoxantrone, mitomycin C, or methotrexate.

21. (Previously Presented) The method of claim 15 wherein the administration provides a 5-substituted nucleoside blood concentration between 0.02 and 50 µg/ml during the recovery phase.

22. (Previously Presented) The method of claim 15 wherein the administration provides a 5-substituted nucleoside blood concentration between 0.02 and 50 µg/ml during the cytostatic chemotherapy cycle.

23. (Canceled)

24. (Previously Presented) The method of claim 15 wherein the recovery phase has a duration of from 3 to 10 days.

25. (Currently Amended) The method of claim 24 wherein the cytostatic chemotherapy cycle has a duration of from 8 to 30 days.

26. (Currently Amended) The method of claim 15 wherein the cytostatic chemotherapy cycle has a duration of from 8 to 30 days.

27. (Canceled)

28. (Previously Presented) The method of claim 9 ~~wherein the 5'-substituted nucleoside administered 8 comprising administering~~ during the recovery phase ~~comprises a compound the BVDU prodrug~~ of the general formula I:

